Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017
ROCKVILLE, MD, July 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as …